The Icelandic pharmaceutical reimbursement authority has approved the new price and decided to grant full reimbursement to Metvix. The price will be equal to a Scandinavian average plus 15%, and the decision will be effective as of May 1st 2008.
The decision is based on Icelandic patients´ benefit from using Metvix®/Aktilite® as an effective and non-invasive treatment for skin cancer, in addition to health economic analyses showing that Metvix represents good value for money to the health care service and to society.
Metvix PDT is approved in the EU/EEA for treatment of actinic keratosis, Bowen's Disease and Basal Cell Carcinoma. Metvix PDT is a skin cancer treatment that combines local application of a cream (Metvix), selectively absorbed into the cancer cells, and illumination with a proprietary red light source (Aktilite) to activate the drug.
Photocure®, Metvix® and Aktilite® are registered trademarks of Photocure ASA.